CN103420981A - Substituted-pyrrolidinyl-contained thiomorpholine compounds - Google Patents
Substituted-pyrrolidinyl-contained thiomorpholine compounds Download PDFInfo
- Publication number
- CN103420981A CN103420981A CN2012101596323A CN201210159632A CN103420981A CN 103420981 A CN103420981 A CN 103420981A CN 2012101596323 A CN2012101596323 A CN 2012101596323A CN 201210159632 A CN201210159632 A CN 201210159632A CN 103420981 A CN103420981 A CN 103420981A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- formyl
- thiomorpholine
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004886 thiomorpholines Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 131
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract description 55
- 238000002360 preparation method Methods 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002018 overexpression Effects 0.000 claims abstract description 9
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract description 8
- -1 benzyl-formyl Chemical group 0.000 claims description 89
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 54
- 125000003118 aryl group Chemical group 0.000 claims description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 201000001421 hyperglycemia Diseases 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 208000013403 hyperactivity Diseases 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001491 aromatic compounds Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 191
- 238000006243 chemical reaction Methods 0.000 description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 50
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 238000004896 high resolution mass spectrometry Methods 0.000 description 22
- 239000012043 crude product Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- 239000003480 eluent Substances 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 18
- 239000007858 starting material Substances 0.000 description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- 239000012224 working solution Substances 0.000 description 14
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000012300 argon atmosphere Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 4
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 4
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 3
- 0 CC**C(C*1)CC1C(*1CCNCC1)=O Chemical compound CC**C(C*1)CC1C(*1CCNCC1)=O 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 101150065749 Churc1 gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038239 Protein Churchill Human genes 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- GJQNVZVOTKFLIU-UHFFFAOYSA-N piperidin-1-ium-4-one;chloride Chemical compound Cl.O=C1CCNCC1 GJQNVZVOTKFLIU-UHFFFAOYSA-N 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VBBFIBMVFSUUBP-MERQFXBCSA-N (2S)-1-(2-aminoacetyl)-N-(4-nitrophenyl)pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 VBBFIBMVFSUUBP-MERQFXBCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- KMAQZIILEGKYQZ-UHFFFAOYSA-N 1-chloro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Cl)=C1 KMAQZIILEGKYQZ-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical group O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- WRXVOTDGLNPNND-UHFFFAOYSA-N 3-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=CC(C#N)=C1 WRXVOTDGLNPNND-UHFFFAOYSA-N 0.000 description 1
- JJMOMMLADQPZNY-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanal Chemical compound OCC(C)(C)C=O JJMOMMLADQPZNY-UHFFFAOYSA-N 0.000 description 1
- LOQLDQJTSMKBJU-UHFFFAOYSA-N 4-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=C(C#N)C=C1 LOQLDQJTSMKBJU-UHFFFAOYSA-N 0.000 description 1
- GJNGXPDXRVXSEH-UHFFFAOYSA-N 4-chlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C=C1 GJNGXPDXRVXSEH-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- QLKYOINYKWSUIO-UHFFFAOYSA-N 6-(4-oxopiperidin-1-yl)pyridine-3-carbonitrile Chemical compound C1CC(=O)CCN1C1=CC=C(C#N)C=N1 QLKYOINYKWSUIO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940127004 drugs for type 2 diabetes Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000045598 human DPP4 Human genes 0.000 description 1
- 102000052412 human DPP8 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses substituted-pyrrolidinyl-contained thiomorpholine compounds, a preparation method thereof and applications thereof. In concrete, the invention relates to compounds having a general formula (I), stereoisomers of the compounds and pharmaceutical acceptable salts of the compounds, wherein R is shown in the specification. The invention also relates to pharmaceutical compositions comprising the compounds, and the applications of the compounds in preparing medicines used for treating and/or preventing a disease or a symptom which are related to over-high activity of DPP-IV or over-expression of the DPP-IV, and also relates to a method of using the compounds for treating related diseases. The compounds have activity for effectively inhibiting the DPP-IV.
Description
Technical Field
The invention belongs to the technical field of medicines. Relates to a thiomorpholine compound containing substituted pyrrolidinyl as shown in general formula (I), pharmaceutically acceptable salt and isomer thereof, preparation of the compound, a pharmaceutical composition containing the compound and application of the compound in preventing and/or treating diabetes and non-insulin-dependent diabetes, in particular to application in inhibiting DPP-IV.
Background
Diabetes is a chronic metabolic disease, and the main manifestation of patients is hyperglycemia. Persistent hyperglycemia can lead to a number of complications, such as retinal, renal, nervous, and microvascular complications. Currently, about 2.46 million people worldwide have type 2 diabetes, and the number of patients is expected to reach 3.8 million within 20 years [ xu Si Sheng, research progress of novel antidiabetic drugs, proceedings of Chinese university of pharmacy 2011,42(2):97-106 ]. Diabetes has become a number 3 killer threatening human health following cardiovascular disease and cancer, with type 2 diabetic patients accounting for over 90% of the total number of diabetic patients. The commonly used clinical antidiabetic drugs comprise insulin, biguanides, sulfonylureas, glycosidase inhibitors, thiazolidinediones and the like, but the treatment effect is limited and has adverse reactions of different degrees: such as insulin, can increase body weight and increase the risk of hypoglycemia, while daily administration of injections can lead to poor patient compliance; biguanides, although first-line drugs for type 2 diabetes, have gastrointestinal side effects and may cause lactic acidosis in renal incompetent patients [ Duez H, DPP-4inhibitors in the treatment of type 2 diabetes [ J ]. Biochem Pharm,2012,83:823-832 ].
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can promote insulin release and inhibit glucagon secretion when blood sugar is increased, and can stimulate insulin gene expression, promote insulin synthesis and beta cell proliferation, and play important roles in the in vivo blood sugar regulation process. Endogenous GLP-1 and GIP can be rapidly degraded and inactivated by dipeptidyl peptidase IV (DPP-IV) in vivo, and the half-life is very short. The DPP-IV inhibitor can increase the concentration of endogenous GIP and GLP-1 in blood, thereby effectively promoting insulin secretion, reducing blood sugar, protecting beta cell function, and not causing the side effects of hypoglycemia and weight gain.
With the intensive research on the DPP family, especially DPP8 and DPP9, since DPP8, DPP9 and DPP-IV have certain similarities in protein structure and substrate type, when DPP-IV inhibitor is less selective, simultaneous action on DPP8/9 can produce serious side effects such as alopecia, thrombocytopenia and anemia [ Havale SH, medical chemistry apoptosis to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 Diabetes, bioorg Med Chem Lett,2009,17: 1783-. Therefore, the DPP-IV inhibitor has to have high selectivity to a single DPP-IV target so as not to influence the normal physiological functions of other DPPs, which is also a difficult point and a key point for developing novel selective DPP-IV inhibitors.
Therefore, there is still a need in the art for new and potent selective DPP-IV inhibitors to meet the needs of clinical therapy.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a selective DPP-IV inhibitor with a novel structure and strong activity. The inventor finds that the thiomorpholine compound containing the substituted pyrrolidinyl has stronger inhibitory activity and selectivity on DPP-IV, thereby providing a selective DPP-IV inhibitor with novel structure and strong activity, which can be used for preventing and treating diabetes. The present invention has been completed based on the above findings.
Summary of The Invention
To this end, the present invention provides, in a first aspect, compounds of formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts thereof,
wherein,
r is selected from hydrogen and C1-6Alkyl radical, C3-8Cycloalkyl, aryl-C1-3Alkyl, aryl-C3-8Cycloalkyl, heteroaryl-C1-3Alkyl, heteroaryl-C3-8Cycloalkyl radicals containing from 3 to 8 (e.g. 3 to 7, 3 to 6, 3 to 5, or 3 to 4) carbon atoms and from 1 to 3 (e.g. 1 to 2, 1, 2, or 3) atoms selected from nitrogen, oxygenHetero-atomic heterocycloalkyl of sulfur, aryl-C3-8Heterocycloalkyl, heteroaryl-C3-8Heterocycloalkyl, benzyl-C3-8Heterocycloalkyl radical, C1-6Alkyl formyl radical, C3-8Cycloalkyl-formyl, aryl-formyl, benzyl-formyl, heteroaryl-formyl, C1-6Alkylsulfonyl radical, C3-8Cycloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, benzylsulfonyl; wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Group, and NR1R2And R is1And R2Independently selected from H, C1-6Alkyl, etc.;
a compound according to any one of the first aspect of the invention which is a compound of formula (IA) and stereoisomers thereof, pharmaceutically acceptable salts thereof,
wherein,
r is selected from hydrogen and C1-6Alkyl radical, C3-8Cycloalkyl, aryl-C1-3Alkyl, aryl-C3-8Cycloalkyl, heteroaryl-C1-3Alkyl, heteroaryl-C3-8Cycloalkyl, heterocycloalkyl containing from 3 to 8 (e.g. 3 to 7, 3 to 6, 3 to 5, or 3 to 4) carbon atoms and from 1 to 3 (e.g. 1 to 2, 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, sulfur, aryl-C3-8Heterocycloalkyl, heteroaryl-C3-8Heterocycloalkyl, benzyl-C3-8Heterocycloalkyl radical, C1-6Alkyl formyl radical, C3-8Cycloalkyl-formyl, aryl-formyl, benzyl-formyl, heteroaryl-formyl, C1-6Alkylsulfonyl radical, C3-8Cycloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, benzylSulfonyl, wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6Alkyl, etc.;
a compound according to any one of the first aspect of the invention which is a compound of formula (IA) and stereoisomers thereof, pharmaceutically acceptable salts thereof, wherein
R is selected from C1-6Alkyl, aryl, heteroaryl, C3-8Nitrogen-containing heterocycloalkyl, aryl-C1-3Alkyl, heteroaryl-C1-3Alkyl, arylsulfonyl, heteroaryl-C3-8Nitrogen-containing heterocycloalkyl, benzyl-C3-8Nitrogen-containing heterocycloalkyl, etc.; wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
A compound according to any one of the first aspect of the present invention, and stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein,
r is C1-6Alkyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted phenyl-C1-3Alkyl, substituted or unsubstituted pyridyl-C1-3Alkyl, substituted or unsubstituted pyridyl-piperidyl, substituted or unsubstituted benzyl-piperidyl, substituted or unsubstituted benzenesulfonyl, and the like; wherein said alkyl, piperidinyl, phenyl, pyridinyl, quinolinyl, and benzyl are optionally substituted with 1-4 (e.g., 1-3, 1-2, 1, 2, or 3)Substituted from the following groups: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
R is preferably 2, 2-dimethyl-3-hydroxypropyl, piperidinyl, phenyl, 4-methylphenyl, 4-cyanophenyl, 4-trifluoromethylphenyl, 3-nitrophenyl, pyridin-2-yl, 5-cyano-pyridin-2-yl, 3-cyano-pyridin-2-yl, quinolin-2-yl, 3, 4-dimethoxybenzyl, 4-cyanobenzyl, pyridin-2-yl-methyl, (5-cyanopyridin-2-yl) -piperidin-4-yl, 4-cyanobenzylpiperidin-4-yl, p-nitrobenzenesulfonyl, p-methylbenzenesulfonyl or the like.
The pharmaceutically acceptable salts described in the present invention are salts of the compounds of the present invention with an acid selected from the group consisting of: hydrochloric acid, p-toluenesulfonic acid, tartaric acid, maleic acid, lactic acid, methanesulfonic acid, sulfuric acid, phosphoric acid, citric acid, acetic acid or trifluoroacetic acid. Preferably hydrochloric acid, p-toluenesulfonic acid or trifluoroacetic acid.
A compound according to any one of the first aspect of the present invention, which is the subject compound of the present invention prepared in the examples (represented by structural formula or described by systematic name) and stereoisomers thereof, and pharmaceutically acceptable salts thereof.
A compound according to any one of the first aspect of the invention, which is a compound selected from:
in a second aspect, the present invention provides a process for the preparation of a compound according to any one of the first aspect of the invention, comprising the steps of:
reacting a compound of formula 1a with (Boc) in a solvent (e.g., water, dioxane, or a mixture thereof) in the presence of a base (e.g., an inorganic base such as sodium hydroxide or an organic base such as triethylamine) at a temperature of-10 ℃ to 40 ℃ (e.g., -10 ℃ to 35 ℃, -5 ℃ to 30 ℃, -5 ℃ to 25 ℃, or 0 ℃ to 25 ℃)2And O reacts for 2 to 12 hours to obtain the compound shown as the formula 2 a.
Reacting the compound of formula 2a with thiomorpholine in an organic solvent (e.g., N-dimethylformamide) at a temperature of 10 ℃ to 40 ℃ (e.g., 10 ℃ to 35 ℃, 15 ℃ to 30 ℃,20 ℃ to 30 ℃, or 20 ℃ to 25 ℃) in the presence of 1-2 equivalents of a condensing agent (e.g., EDCI, HOBT, or a mixture of both) and a base (e.g., triethylamine) for 4-8 hours to provide the compound of formula 3 a.
The compound represented by formula 3a is reacted with sulfonyl chloride (e.g., methanesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride, or the like) in a solvent (e.g., dichloromethane) at a temperature of-10 ℃ to 10 ℃ (e.g., -5 ℃ to 10 ℃,0 ℃ to 10 ℃, or 5 ℃ to 10 ℃) in the presence of a base (e.g., triethylamine) for 1-5 hours to give the compound represented by formula 4 a.
Reacting the compound represented by formula 4a with sodium azide at a temperature of 60 ℃ to 90 ℃ (e.g., 60 ℃ to 70 ℃, 70 ℃ to 80 ℃, or 80 ℃ to 90 ℃) in a solvent (e.g., N-dimethylformamide) for 4-6 hours to obtain the compound represented by formula 5 a.
The compound of formula 5a is reduced by hydrogenation over a catalyst (e.g., palladium on charcoal) in a solvent (e.g., methanol or ethanol) at room temperature (e.g., 15 ℃ to 25 ℃) for 5 to 8 hours to provide the compound of formula 6 a.
Subjecting the compound of formula 6a to a substitution reaction with a halide RX (X is halogen) in a base (e.g. potassium carbonate) and a suitable solvent (e.g. N, N-dimethylformamide) at a temperature of 60 ℃ to 90 ℃ (e.g. 60 ℃ to 70 ℃, 70 ℃ to 80 ℃ or 80 ℃ to 90 ℃) for about 4 to 12 hours to give a compound of formula b; or,
reacting a compound of formula 6a with an aldehyde or ketone containing an R group under acidic conditions (e.g., acetic acid) at a temperature of-10 ℃ to 40 ℃ (e.g., -10 ℃ to 35 ℃, -5 ℃ to 30 ℃, -5 ℃ to 25 ℃, or 0 ℃ to 25 ℃) for about 2-6 hours to provide a compound of formula b; or,
reacting the compound of formula 6a with a sulfonyl chloride containing an R group in a base (e.g., triethylamine) and a suitable solvent (e.g., dichloromethane) at a temperature of-20 ℃ to 0 ℃ (e.g., -20 ℃ to 0 ℃, -15 ℃ to 0 ℃, or-5 ℃ to 0 ℃) for about 2-6 hours to provide a compound of formula b; or,
the compound of formula 6a is reacted with the halogenated aromatic compound containing the R group using a suitable ligand such as Davep and a catalyst such as palladium acetate in a base such as sodium t-butoxide and a suitable solvent such as toluene at a temperature of 90 c to 150 c (e.g., 100 c to 150 c, 110 c to 150 c or 130 c to 150 c) for about 8 to 16 hours to provide the compound of formula b.
The Boc protecting group is removed from the compound of formula b in ethyl acetate hydrochloride solution at a temperature of 10 ℃ to 40 ℃ (e.g., 10 ℃ to 35 ℃, 15 ℃ to 30 ℃,20 ℃ to 30 ℃ or 20 ℃ to 25 ℃) to provide the compound of the invention of formula IA. If racemic 1a is used as the raw material, the compound of the invention shown in the formula I is obtained according to the steps and the method.
Wherein R is as defined in the first aspect of the invention.
In a third aspect, the present invention provides a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of a compound according to any one of the first aspect of the present invention and stereoisomers thereof, pharmaceutically acceptable salts thereof, and optionally one or more pharmaceutically acceptable carriers or excipients.
The fourth aspect of the present invention provides a compound according to any one of the first aspect of the present invention and stereoisomers, pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to any one of the third aspect of the present invention, for use in the manufacture of a medicament for the treatment and/or prevention of diseases or conditions associated with DPP-IV hyperactivity or DPP-IV overexpression. In one embodiment, the disease or condition associated with DPP-IV hyperactivity or DPP-IV overexpression is a disease or condition selected from: diabetes, hyperglycemia, non-insulin dependent diabetes, type 2 diabetes, and the like.
The fourth aspect of the present invention also provides a compound according to any one of the first aspect of the present invention and stereoisomers, pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to any one of the third aspect of the present invention, for use in the manufacture of a medicament for the treatment and/or prophylaxis of diabetes, hyperglycemia, non-insulin dependent diabetes, type 2 diabetes and the like.
The fourth aspect of the present invention also provides a compound according to any one of the first aspect of the present invention and stereoisomers, pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to any one of the third aspect of the present invention for use in the manufacture of a medicament for use as a DPP-IV inhibitor.
In a fifth aspect, the present invention provides a method for treating and/or preventing diseases or disorders associated with DPP-IV hyperactivity or DPP-IV overexpression in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically and/or prophylactically effective amount of a compound according to any one of the first aspect of the present invention, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of the third aspect of the present invention. The method according to the fifth aspect of the present invention, wherein the disease or disorder associated with DPP-IV hyperactivity or DPP-IV overexpression is selected from diabetes, hyperglycemia, non-insulin dependent diabetes mellitus, type 2 diabetes and the like.
The fifth aspect of the present invention also provides a method for the treatment and/or prophylaxis of diabetes, hyperglycemia, non-insulin dependent diabetes mellitus, type 2 diabetes in a subject in need thereof, which comprises administering to the subject in need thereof a therapeutically and/or prophylactically effective amount of a compound according to any one of the first aspect of the present invention and stereoisomers thereof, pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to any one of the third aspect of the present invention.
In a sixth aspect, the present invention provides a compound according to any one of the first aspect of the present invention and stereoisomers thereof, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prevention of diseases or conditions associated with DPP-IV hyperactivity or DPP-IV overexpression. A compound according to a sixth aspect of the present invention, wherein said disease or condition associated with DPP-IV hyperactivity or DPP-IV overexpression is selected from: diabetes, hyperglycemia, non-insulin dependent diabetes, type 2 diabetes, and the like.
The sixth aspect of the present invention also provides a compound according to any one of the first aspect of the present invention and stereoisomers thereof, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prevention of diabetes, hyperglycemia, non-insulin dependent diabetes, type 2 diabetes and the like.
Any aspect of the invention or any one of the aspects having features is equally applicable to any other aspect or any one of the other aspects as long as they are not mutually inconsistent, although appropriate modifications to the respective features may be made as necessary when applicable to each other. In the present invention, for example, reference to "any of the first aspects of the invention" means any sub-aspect of the first aspects of the invention, and in other respects similarly referred to, has similar meaning.
Detailed description of the invention:
various aspects and features of the disclosure are described further below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure. The following are definitions of various terms used herein, which apply to the terms used throughout the specification of the present application unless otherwise specified in specific instances.
The term "alkoxy" refers to alkyl-O-, wherein alkyl is as described herein.
As used herein, the terms "halo", "halogen atom", "halo", and the like, denote fluorine, chlorine, bromine, or iodine, and particularly denote fluorine, chlorine, or bromine.
As used herein, the term "alkyl" refers to an alkyl group having the specified number of carbon atoms, which is a straight or branched chain alkyl group, and which may include sub-groups thereof, such as the instant "C" group1-6When "alkyl", it may also include C1-5Alkyl radical, C1-4Alkyl radical, C2-6Alkyl radical, C2-4Alkyl, etc., and specific groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl.
The term "aryl" as described herein, alone or in combination, is defined herein as a monocyclic or bicyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and the like. Similarly, the term "aryloxy-" refers to an aryl group that is attached to the rest of the compound through an oxygen.
As used herein, the term "heteroaryl" refers herein to aryl groups having from 1 to 3 heteroatoms as ring atoms, the remaining ring atoms being carbon, the heteroatoms including oxygen, sulfur and nitrogen. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, imidazolyl, furyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, and the like. In one embodiment, the heteroaryl is pyridyl, quinolyl.
The term "aryl-C" as described herein1-3Alkyl- "means an aryl group, which is bonded through C1-3Alkyl groups are attached to the rest of the compound.
The term "heteroaryl-C" as described herein1-3Alkyl- "means a heteroaryl group, which is bonded through C1-3Alkylation withThe other part of the compound is attached.
As used herein, the term "cycloalkyl" refers to a cyclic alkyl group having the number of ring carbon atoms specified, and which may include a sub-group thereof, such as, for example, the time "C3-8When cycloalkyl "is present, it may also include C3-7Cycloalkyl radical, C3-6Cycloalkyl radical, C3-5Cycloalkyl radical, C4-7Cycloalkyl, and the like, as well as specific groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
As used herein, the term "heterocycloalkyl" refers to a cyclic heteroalkyl group having the indicated number of ring atoms, including monocyclic or fused ring groups, having from 5 to 9 ring atoms in the ring, wherein one or two ring atoms are heteroatoms selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms are carbon. The rings may also have one or more double bonds, however, the rings do not have a completely conjugated n-electron system. Heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and the like.
As used herein, the term "effective amount" refers to a dose that achieves treatment and/or prevention of a disease or disorder described herein in a subject.
As used herein, the term "pharmaceutical composition" may also refer to a "composition" that may be used to effect treatment and/or prevention of a disease or disorder described herein in a subject, particularly a mammal.
As used herein, the term "subject" can refer to a patient or other animal, particularly a mammal, e.g., a human, dog, monkey, cow, horse, etc., that receives a compound of formula I of the invention or a pharmaceutical composition thereof for the treatment and/or prevention of a disease or disorder described herein.
As used herein, the term "disease and/or disorder" refers to a physical condition of the subject that is associated with the disease and/or disorder of the present invention. For example, the disease and/or condition of the present invention may refer to a physical condition, such as a physical condition exhibiting elevated blood glucose levels, or a disease condition, such as a disease condition characterized by hyperglycemia, diabetes, and the like. The body state and the disease state are not distinguished herein or may be referred to one another, e.g., "hyperglycemia" may be used interchangeably with "hyperglycemia".
As used herein, "%" refers to weight/weight percentages, particularly where solid matter is described, as well as where not specifically indicated. Of course, in describing liquid materials, the "%" may refer to weight/volume percentages (for the case of solids dissolved in liquids) or may refer to volume/volume percentages (for the case of liquids dissolved in liquids).
As used herein, the term "pharmaceutically acceptable" when describing a "pharmaceutically acceptable salt" means not only that the salt is physiologically acceptable to the subject, but may also refer to a synthetic substance of pharmaceutical value, e.g., a salt formed as an intermediate in order to effect chiral resolution, which salt may play a role in achieving the end product of the invention, although such intermediate salt may not be directly administered to the subject.
In a further aspect, the invention relates to pharmaceutical compositions comprising as active ingredient a compound of the invention. The pharmaceutical composition may be prepared according to methods well known in the art. The compounds of the invention may be formulated into any dosage form suitable for human or animal use by combining them with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants. The compounds of the present invention are generally present in the pharmaceutical compositions in an amount of from 0.1 to 95% by weight.
The compounds of the present invention or pharmaceutical compositions containing them may be administered in unit dosage form by enteral or parenteral routes, such as oral, intravenous, intramuscular, subcutaneous, nasal, oromucosal, ophthalmic, pulmonary and respiratory, dermal, vaginal, rectal, and the like.
The dosage form for administration may be a liquid dosage form, a solid dosage form, or a semi-solid dosage form. The liquid dosage forms can be solution (including true solution and colloidal solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including water injection, powder injection and infusion), eye drop, nose drop, lotion, liniment, etc.; the solid dosage form can be tablet (including common tablet, enteric coated tablet, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet), capsule (including hard capsule, soft capsule, and enteric coated capsule), granule, powder, pellet, dripping pill, suppository, pellicle, patch, aerosol (powder), spray, etc.; semisolid dosage forms can be ointments, gels, pastes, and the like.
The compound can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various particle drug delivery systems.
For tableting the compound of the present invention, a wide variety of excipients known in the art may be used, including diluents, binders, wetting agents, disintegrants, lubricants, and solubilizers. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the humectant can be water, ethanol, isopropanol, etc.; the binder can be starch slurry, dextrin, syrup, Mel, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and cosolvent may be talc, silica, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets.
To encapsulate the administration unit, the active ingredient of the compound of the present invention may be mixed with a diluent and a cosolvent, and the mixture may be directly placed in a hard capsule or soft capsule. Or the effective component of the compound of the invention can be prepared into granules or pellets with diluent, adhesive and disintegrating agent, and then placed into hard capsules or soft capsules. The diluents, binders, wetting agents, disintegrants, and cosolvents used to prepare the compound tablets of the present invention can also be used to prepare capsules of the compounds of the present invention.
For preparing the compound of the present invention into injection, water, ethanol, isopropanol, propylene glycol or their mixture can be used as solvent, and appropriate amount of solubilizer, cosolvent, pH regulator, and osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-beta-cyclodextrin, etc.; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. For example, mannitol and glucose can be added as proppant for preparing lyophilized powder for injection.
In addition, colorants, preservatives, flavors, or other additives may also be added to the pharmaceutical preparation, if desired.
For the purpose of administration and enhancing the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.
The dosage of the pharmaceutical composition of the compound of the present invention to be administered may vary widely depending on the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route and dosage form of administration, and the like. Generally, a suitable daily dosage range for a compound of the invention is from 0.001 to 150mg/Kg body weight, preferably from 0.1 to 100mg/Kg body weight, more preferably from 1 to 60mg/Kg body weight, and most preferably from 2 to 30mg/Kg body weight. The above-described dosage may be administered in one dosage unit or divided into several dosage units, depending on the clinical experience of the physician and the dosage regimen including the use of other therapeutic means.
The compounds or compositions of the present invention may be administered alone or in combination with other therapeutic or symptomatic agents. When the compound of the present invention is used in a synergistic manner with other therapeutic agents, the dosage thereof should be adjusted according to the actual circumstances.
Advantageous technical effects
The inventor finds that the in vitro DPP-IV inhibitory activity of most of thiomorpholine compounds containing substituted pyrrolidine reaches more than 50%, wherein the IC of 9 compounds50The DPP-IV inhibitor reaches micromolar level, has low inhibition rate to DPP8 and DPP9, shows good DPP-IV selectivity, and thus, provides a selective DPP-IV inhibitor with novel structure and strong activity, and can be used for preventing and treating diabetes.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible.
For all of the following examples, standard procedures and purification methods known to those skilled in the art may be used. Unless otherwise indicated, all temperatures are expressed in degrees centigrade (degrees celsius). The structure of the compounds is determined by nuclear magnetic resonance spectroscopy (NMR) and/or Mass Spectrometry (MS). m.p. is the melting point given at ℃, temperature uncorrected.
Preparation examples section
The structure of the compound is as followsNuclear magnetic resonance hydrogen spectrum (1H NMR) and Mass Spectrometry (MS). The hydrogen and carbon spectral shifts (δ) for nuclear magnetic resonance are given in parts per million (ppm). NMR spectra were obtained using a Mercury-300 or Mercury-400 NMR spectrometer, deuterated chloroform (CDCl)3) Or heavy water (D)2O) or deuterated dimethyl sulfoxide (DMSO-d)6) As solvent Tetramethylsilane (TMS) was used as internal standard.
The melting point was measured using a Yanaco model M.P-500D melting point tester, Japan, and the temperature was not corrected.
The high resolution mass spectrum was measured using an Agilent 1100series LC/MSD trap mass spectrometer.
The specific optical rotation was measured using a Perkin-Elmer model 241MC polarimeter under sodium light at 20 ℃.
The electronic balance used was an electronic balance model Yanaco LY-300, Japan.
The column chromatography generally uses 200-300 mesh silica gel as a carrier.
The anhydrous solvents were all processed by standard methods. Other reagents were all commercially available analytical grade.
Wherein,
(Boc)2o is Di-tert-butyl dicarbanate, namely Di-tert-butyl dicarbonate.
AcOH is an Acetic Acid, i.e., Acetic Acid.
DMF is N, N-Dimethylformamide, i.e., N-Dimethylformamide.
EDCI is 1- (3- (dimethylamino) propyl) -3-ethylcarbodiimide hydrochloride, i.e., 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride.
HOBT is 3-hydroxy-benzotriazole hydrate, namely 1-hydroxybenzotriazole.
Davep is 2-dicyclohexylphosphino-2 '- (N, N-dimethyllamino) biphenyl, i.e., 2-dicyclohexylphosphino-2' - (N, N-dimethylamino) biphenyl.
Preparation example
Synthetic route of Scheme 1 intermediate 6a
First step preparation of (2S, 4R) -N-tert-Butoxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid 2a
4-OH-L-proline (3.95g,30.1mmol) was dissolved in 50mL of 1, 4-dioxane and 50mL of 1 mol. L-1Adding (Boc) to a mixed solution of sodium hydroxide solution at 0 deg.C2O (7.85g, 36.0mmol), stirred at low temperature for 0.5h, then warmed to room temperature and stirred overnight. Concentrating under reduced pressure, steaming to near dryness, dissolving in 50mL of water, and dissolving with 1 mol/L-1Adjusting the pH value of the HCl solution to 2-3, extracting with ethyl acetate, combining organic layers, washing the organic layers with saturated saline solution, drying with anhydrous sodium sulfate, filtering, and concentrating under reduced pressure to obtain an intermediate 2a which is 6.68g of white solid with the yield of about 96.3%.1H NMR(D2O,300MHz)δ:4.53(br,1H,CH-OH in pyrrolidine),4.42-4.36(m,1H,CHC=O),3.60-3.47(m,2H,CH2N in pyrrolidine),2.42-2.35&2.19-2.10(m,2H,CH2CHC=O in pyrrolidine),1.43(s,9H,Boc).
Second step preparation of 4- { [ (2S, 4R) -N-tert-Butoxycarbonyl-4-hydroxy-pyrrol-2-yl ] -formyl } thiomorpholine 3a
(2S, 4R) -N-tert-Butoxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid 2a (5.77g,25.0mmol) was dissolved in 50mL of anhydrous DMF and EDCI (5.82g,30.3mmol) and HOBT (4.06g,30.1mmol) were added and after complete dissolution thiomorpholine (2.83g,27.5mmol) and triethylamine (5.06g,50.1mmol) were added and stirred at room temperature overnight to completion. 50mL of ice water was added to the reaction system and stirred for 30 min. Extracting with ethyl acetate, combining organic layers, washing the organic layers with water and saturated sodium chloride water respectively, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, separating the obtained crude product by silica gel (200-300 meshes) column chromatography, and taking dichloromethane-methanol (V: V = 50: 1) mixed solution as an eluent to obtain an intermediate 3a, 5.94g of white solid, and the yield is 75.2%.
1H NMR(CDCl3,300MHz)δ:4.83-4.69(m,1H,CHC=O),4.55-4.50(br,1H,CH-NH2 in pyrrolidine),3.97-3.79(m,4H,CH2NCH2 in thiomorpholine),3.70-3.48(m,2H,CH2N in pyrrolidine),2.68-2.58(m,4H,CH2SCH2 in thiomorpholine),2.28-2.03(m 2H CH 2 CHC=O in pyrrolidine)1.45(s 9H Boc)HR-MS(ESI-TOF+):C14H25N2O4S calculated value 317.1530, found [ M + H]+317.1502.
Third step preparation of 4- { [ (2S, 4R) -N-tert-Butoxycarbonyl-4-methanesulfonyl-pyrrol-2-yl ] -formyl } thiomorpholine 4a
4- { [ (2S, 4R) -N-tert-Butoxycarbonyl-4-hydroxy-pyrrol-2-yl ] -formyl } thiomorpholine 3a (5.37g,17.0mmol) was dissolved in 50mL of anhydrous dichloromethane, triethylamine (2.58g,25.5mmol) was added, the reaction system was cooled to below 0 deg.C, methanesulfonyl chloride (1.9mL,24.5mmol) was slowly added dropwise, and the reaction was allowed to proceed at low temperature for 2 hours until completion (TLC trace). The reaction solution was warmed to room temperature, and the organic phase was washed successively with distilled water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was chromatographed on silica gel (200-300 mesh) using dichloromethane-methanol (V: V = 50: 1) as eluent to give intermediate 4a as a white solid (6.53 g, 97.5% yield).
1H NMR(CDCl3,300MHz)δ:5.32-5.24(br,1H,CH-OSO2CH3 in pyrrolidine),4.88-4.71(m,1H,CHC=O in pyrrolidine),4.00-3.97(m,2H,CH2N in pyrrolidine),3.90-3.77(m,4H,CH2NCH2 in thiomorpholine),3.05(s,3H,CH3),2.89-2.21(m,6H,CH2SCH2 in thiomorpholine,CH 2 CHC=O in pyrrolidine),1.25(s,9H,Boc).HR-MS(ESI-TOF+):C15H27N2O6S2Calculated value 395.1305, found [ M + H]+395.1272.
Step four preparation of 4- { [ (2S,4S) -4-azido-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 5a
4- { [ (2S, 4R) -N-tert-butoxycarbonyl-4-methanesulfonyl-pyrrol-2-yl ] -formyl } thiomorpholine 4a (6.30g,16.0mmol) was dissolved in 30mL of anhydrous DMF, sodium azide (1.56g,24.0mmol) was added, reaction was carried out at 80 ℃ for 5 hours until completion, 30mL of ice water was added to the reaction system, stirring was carried out for 30 minutes, extraction was carried out with ethyl acetate, the organic layers were combined, washed with water and saturated brine respectively, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting crude product was subjected to column chromatography on silica gel (200-300 mesh) using a petroleum ether-ethyl acetate (V: V = 1: 1) mixture as an eluent, to give intermediate 5a, 4.53g of a white solid, and yield of 82.9%.
1H NMR(CDCl3,300MHz)δ:4.69-4.51(m,1H,CHC=O),4.12-4.03(m,1H,CH-N3 in pyrrolidine),3.95-3.85(m,4H,CH2NCH2 in thiomorpholine),3.79-3.27(m,2H,CH2N in pyrrolidine),2.68-2.48(m,4H,CH2SCH2 in thiomorpholine),2.91-1.88(m,2H,CH 2 CHC=O in pyrrolidine),1.51(s,9H,Boc).HR-MS(ESI-TOF+):C14H24N5O3S calculated value 342.1594, found [ M + H]+342.1654.
Fifth step preparation of 4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a
4- { [ (2S,4S) -4-azido-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 5a (4.42g,13.0mmol) was dissolved in 20mL of methanol, 10% by mass of Pd/C (0.66g, 15% by mass) was added, and the reaction was hydrogenated at medium pressure for 4 hours until completion. The solid in the reaction solution was filtered off, and the crude product was separated by column chromatography on silica gel (200-mesh 300-mesh) using dichloromethane-methanol (V: V = 50: 3, 1mL ammonia per 200 mL) as eluent to give intermediate 6a as a white solid 3.05g with a yield of 74.5%.
1H NMR(CDCl3,300MHz)δ:4.68-4.51(m,1H,CHC=O),4.10-3.93(m,1H,CH-NH2 in pyrrolidine),3.85-3.71(m,4H,CH2NCH2 in thiomorpholine),3.56-3.34(m,2H,CH2N in pyrrolidine),2.83-2.60(m,4H,CH2SCH2 in thiomorpholine),2.44-1.63(m,2H,CH 2 CHC=O in pyrrolidine),1.45(s,9H,Boc).HR-MS(ESI-TOF+):C14H26N3O3S calculated value 316.1689, found [ M + H]+316.1680.
Examples
Example 1
The compound 14- { [ (2S,4S) -4- (piperidin-4-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S, S) -N-tert-Butoxycarbonyl-4- (piperidin-4-yl) amino-pyrrol-2-yl ] -formyl } thiomorpholine 1b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.15g,0.48mmol) and N-Boc-4-piperidone (0.098g,0.49mmol) were dissolved in 10mL of dichloromethane, and then a small amount of AcOH was added to adjust the pH of the reaction system to 3-5, and the mixture was stirred at room temperature for 3 hours, the reaction system was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.317g,1.50mmol) was added, and the mixture was warmed to room temperature and stirred for 6 hours until the reaction was complete. To the reaction solution was added 20mL of water, followed by extraction with dichloromethane, and the organic layers were combined, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was chromatographed on a silica gel (200-300 mesh) column using dichloromethane-methanol (V: V = 50: 1) as eluent. Intermediate 1b was obtained as a pale yellow oil 167mg, yield 69.7%.
Second step preparation of 4- { [ (2S,4S) -4- (piperidin-4-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 1)
Coupling 4- { [ (2S,4S) -N-tert-butoxycarbonyl-4- (piperidin-4-yl) amino-pyrrol-2-yl]-formyl } thiomorpholine 1b (167mg,0.33mmol) and 2mL of ethyl acetate hydrochloride solution (7 mol. L)-1) Mixing, stirring at room temperature for 1 hour, precipitating white solid from clear reaction liquid, and washing the obtained white solid with n-hexane solvent. Compound 1 was obtained as an off-white solid, 108mg, yield 79.2, m.p.>250℃,
1H NMR(DMSO-d6,300MHz)δ:4.65(m,1H,CHC=O in pyrrolidine),3.96(br,1H,CHNH in pyrrolidine),3.78-3.71(m,4H,CH2NCH2 in thiomorpholine),3.59(m,1H,CH in piperidine),2.86(m,4H CH 2 NHCH 2 in piperidine),2.71(m,2H,CH 2 CHC=O in pyrrolidine),2.62(m,4H,CH2SCH2 in thiomorpholine),2.19-1.88(m,6H,CH 2 CHCH 2 in piperidine&NHCHCH 2 NH in pyrrolidine).HR-MS(ESI-TOF+):C14H26N4OS calculated 299.1900, found [ M-3HCl + H]+299.1894。
Example 2
The compound 24- { [ (2S,4S) -4- (3-hydroxy-2, 2-dimethyl-propylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (3-hydroxy-2, 2-dimethylpropano) -pyrrol-2-yl ] -formyl } thiomorpholine 2b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.15g,0.48mmol) and 2, 2-dimethyl-3-hydroxypropanal (0.051g,0.50mmol) were dissolved in 10mL of dichloromethane, and after complete dissolution, a small amount of acetic acid was added to the reaction pH =3-5, and stirred at room temperature for 3 hours, the reaction was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.317g,1.50mmol) was added, and the reaction was warmed to room temperature and stirred for 6 hours until completion. To the reaction solution was added 20mL of water, and the combined organic layers were extracted with dichloromethane, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Separating by column chromatography, and eluting with dichloromethane-methanol (V: V = 100: 3) mixture. Intermediate 2b was obtained as a pale yellow oil 124mg, yield 64.4%.
Second step preparation of 4- { [ (2S,4S) -4- (3-hydroxy-2, 2-dimethyl-propylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 2)
Using 2b (124mg,0.31mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 2 was obtained in a yield of 79.4% as an off-white solid. m.p.207-209 ℃,
1H NMR(DMSO-d6,300MHz)δ:4.66-4.64(m,1H,CHC=O),3.79-3.61(m,4H,CH 2 NH,CH 2 OH),3.35(b r,4H,CH2NCH2 in thiomorpholine),2.83-2.61(m,9H,CH2SCH2 in thiomorpholine,5H in pyrrolidine),0.93(s,6H,CH3CCH3).HR-MS(ESI-TOF+):C14H28N3O2s calculated 302.1897, found [ M-2HCl + H]+302.1893.
Example 3
The compound 34- { [ (2S,4S) -4- (4-pyridin-2-yl-methylamino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (pyridin-2-yl-methylamino) -pyrrol-2-yl ] -formyl } thiomorpholine 3b
4- { [ (2S,4S) -4-amino N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.15g,0.48mmol) and 2-pyridinecarboxaldehyde (0.054g,0.50mmol) were dissolved in 10mL of dichloromethane, and after complete dissolution, a small amount of AcOH was added until the reaction pH =3-5, and the mixture was stirred at room temperature for 3 hours, the reaction was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.315g,1.49mmol) was added, and the mixture was warmed to room temperature and stirred for 5 hours until the reaction was complete. Water was added to the reaction solution, followed by extraction with dichloromethane, and the organic layers were combined, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Separating by column chromatography, and eluting with dichloromethane-methanol (V: V = 100: 3) mixture. Intermediate 3b was obtained as 119mg of a yellow oil, yield 61.1%.
Second step preparation of 4- { [ (2S,4S) -4- (4-pyridin-2-yl-methylamino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 3)
Using 3b (119mg,0.29mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 3 was obtained in the form of an off-white solid (88 mg, yield 73.1%). m.p.97-99 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.65(1H,d,J=4.2Hz,in pyridine),7.96(t,1H,J=7.8Hz,in pyridine),7.64(d,1H,J=7.5Hz,in pyridine),7.49(t,1H,J=6.6Hz,inpyridine),4.70(s,1H,CHC=O,in pyrrolidine),4.37(s,2H,CH2),4.06-4.04(m,1H,CHNH in pyrrolidine),3.85-3.62(m,6H CH2NCH2 in thiomorpholine,CH 2 NH inpyrrolidine),2.69-2.49(m,4H,CH2SCH2 in thiomorpholine),2.88-2.12(m,2H,CH 2 CHC=O in pyrrolidine);HR-MS(ESI-TOF+):C15H23N4OS calculated 307.1587, found [ M-3HCl + H]+307.1583.
Example 4
The compound 44- { [ (2S,4S) -4- (3, 4-dimethoxy-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (3, 4-dimethoxy-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine 4b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.15g,0.48mmol) and 3, 4-dimethoxybenzaldehyde (0.083g,0.50mmol) were dissolved in 10mL of dichloromethane, and after complete dissolution, a small amount of AcOH was added until the reaction pH =3-5, and stirred at room temperature for 3 hours, the reaction was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.315g,1.50mmol) was added, and stirred at room temperature for 5 hours until the reaction was complete. To the reaction solution was added 20mL of water, followed by extraction with dichloromethane, and the organic layers were combined, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Separating by column chromatography, and eluting with dichloromethane-methanol (V: V = 50: 1) mixture. Intermediate 4b was obtained as a pale yellow oil, 148mg, 66.7% yield.
Second step preparation of 4- { [ (2S,4S) -4- (3, 4-dimethoxy-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 4)
Using 4b (148mg,0.32mmol) as a starting material, the procedure was carried out in a similar manner to the second step in example 1 to give compound 4 as an off-white solid (122 mg) with a yield of 87.1%. m.p.161-163 ℃ in,
1H NMR(DMSO-d6,300MHz)δ:7.32(s,1H,aromatic),7.08(d,J=8.7Hz,1H,aromatic),6.99(d,J=8.4Hz,1H,aromatic),4.70-4.64(m,1H,CHC=O),3.85(m,1H,CHNH in pyrrolidine),3.79(s,3H,OCH3),3.77(s,3H,OCH3),3.71(m,4H,CH2NCH2in thiomorpholine),3.55-3.57(m,2H,CH 2 NH in pyrrolidine),2.81-2.63(m,4H,CH2SCH2 in thiomorpholine),2.85-1.99(m,2H,CH 2 CHC=O in pyrrolidine).HR-MS(ESI-TOF+):C15H21N4O3s calculated 366.1846, found [ M-2HCl + H]+366.1843.
Example 5
The compound 54- { [ (2S,4S) -4- (4-cyano-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -1-tert-Butoxycarbonyl-4- (4-cyano-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine 5b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.15g,0.48mmol) and potassium carbonate (0.276g,2.0mmol) were dissolved in 15mL of anhydrous DMF, 4-cyanobenzyl chloride (0.076g,0.50mmol) was added, and the mixture was heated at 80 ℃ for reaction for 8 hours. 30mL of ice water was added to the reaction system, the mixture was stirred for 30min, extracted with ethyl acetate, and the organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was chromatographed on silica gel (200-300 mesh) using dichloromethane-methanol (V: V = 50: 1) as eluent to give intermediate 5b as pale yellow crystals 176mg, 85.3% yield
Second step preparation of 4- { [ (2S,4S) -4- (4-cyano-benzylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 5)
Using 5b (176mg,0.41mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 5 was obtained in the form of an off-white solid (134 mg, yield 81.1%). m.p.194-196 ℃,
1H NMR(DMSO-d6,300MHz)δ:7.93(d,J=8.1Hz,2H,aromatic),7.81(d,J=7.8Hz,2H,aromatic),4.71-4.65(m,1H,CHC=O),4.30(s,2H,CH2),3.79-3.58(m,5H,CH2NCH2 in thiomorpholine&CHNH in pyrrolidine),3.57-3.55(m,2H,CH 2 CHC=Oin pyrrolidine),2.87-2.09(m,2H,CH 2 CHC=O in pyrrolidine),2.74-2.49(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C17H22N4OS calculated 331.1586, found [ M-2HCl + H]+331.1587.
Example 6
The compound 64- { [ (2S,4S) -4- (phenylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (phenylamino) -pyrrol-2-yl ] -formyl } thiomorpholine 6b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.101g,0.32mmol) and bromobenzene (0.046g,0.29mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.058g,0.60mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed for 10 hours under argon atmosphere, cooled to room temperature, and insoluble matter in the reaction system was filtered off and concentrated under reduced pressure. The crude product was separated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 6b as off-white crystals 73mg in 64.4% yield.
Second step preparation of 4- { [ (2S,4S) -4- (phenylamino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 6)
Using 6b (73mg,0.19mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 6 was obtained in the form of a white powder (64 mg) with a yield of 92.5%. m.p.165-167 deg.C,
1H NMR(DMSO-d6,300MHz)δ:6.68-6.53(m,3H,aromatic),7.15-7.10(m,2H,aromatic),5.09-5.05(m,1H,CHC=O),4.12(br,1HCHNH in pyrrolidine),3.76-3.72(m,4H,CH2NCH2 in thiomorpholine),3.12(m,2H,CH 2 NH in pyrrolidine),2.70-2.55(m,4H,CH2SCH2 in thiomorpholine),2.34-1.60(m,2H,CH 2 CHC=O in pyrrolidine).HR-MS(ESI-TOF+):C15H22N3OS calculated 292.1478, found [ M-2HCl + H]+292.1475.
Example 7
The compound 74- { [ (2S,4S) -4- (4-cyanophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (4-cyanophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 7b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.103g,0.33mmol) and 4-cyanochlorobenzene (0.045g,0.33mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.057g,0.59mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed for 10 hours under argon atmosphere, cooled to room temperature, and insoluble matter was filtered off from the reaction system and concentrated under reduced pressure. The crude product was separated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 7b as off-white crystals 77mg in 56.1% yield.
Second step preparation of 4- { [ (2S,4S) -4- (4-cyanophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 7)
Using 7b (77mg,0.19mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 7 was obtained as a white powder in a yield of 57mg, 77.1%. m.p.171-173 ℃,
1H NMR(DMSO-d6,300MHz)δ:7.51(d,J=8.1Hz,2H,aromatic),6.69(d,J=8.4Hz,2H,aromatic),4.65(m,1H,CHC=O),4.24-4.20(m,1H,CHNH in pyrrolidine),3.74-3.72(br,4H CH2NCH2 in thiomorpholine),3.50-3.13(m,2H,CH 2 NH inpyrrolidine),2.81-1.58(m,2H,CH 2 CHC=O in pyrrolidine),2.59(br,4H,CH2SCH2 inthiomorpholine).HR-MS(ESI-TOF+):C16H21N4OS calculated 317.1431, found [ M-2HCl + H]+317.1430.
Example 8
The compound 84- { [ (2S,4S) -4- (4-trifluoromethylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (4-trifluoromethylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 8b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.104g,0.33mmol) and 4-trifluoromethylbromobenzene (0.074g,0.33mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.061g,0.63mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed under argon atmosphere for 10 hours, cooled to room temperature, and insoluble matter was filtered off and concentrated under reduced pressure. The crude product was isolated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 8b as a pale yellow oil 93mg with 61.4% yield.
Second step preparation of 4- { [ (2S,4S) -4- (4-trifluoromethylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 8)
Using 8b (93mg,0.20mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 8 was obtained as a white powder in an yield of 72mg, 83.3%. m.p.141-143 ℃,
1H NMR(DMSO-d6,300MHz)δ:7.44(d,J=8.7Hz,2H,aromatic),6.72(d,J=8.7Hz,2H,aromatic),4.66(br,1H,CHC=O),4.22-4.19(m,1H,CHNH in pyrrolidine),3.78-3.24(m,4H CH2NCH2 in thiomorpholine),3.35-3.14(br,2H,CH 2 NH inpyrrolidine),2.90-1.59(m,2H,CH 2 CHC=O in pyrrolidine),2.80-2.64(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C16H21N3OSF3calculated value 360.1353, found [ M-2HCl + H]+360.1357.
Example 9
The compound 94- { [ (2S,4S) -4- (4-methylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (4-methylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 9b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.102g,0.32mmol) and 4-bromotoluene (0.056g,0.33mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.061g,0.64mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed under argon atmosphere for 16 hours, cooled to room temperature, and insoluble matter was filtered off from the reaction system and concentrated under reduced pressure. The crude product was separated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 9b as a pale yellow oil 78mg with a yield of 60.2%.
Second step preparation of 4- { [ (2S,4S) -4- (4-methylphenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 9)
Using 9b (78mg,0.19mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 9 was obtained as a white powder in a yield of 67mg and 93.3%. m.p.167-169 ℃ of,
1H NMR(DMSO-d6,300MHz)δ:7.30(d,J=7.8Hz,2H,aromatic),6.94(d,J=7.5Hz,2H,aromatic),4.95(br,1H,CHC=O),4.44(m,1H,CHNH in pyrrolidine),4.09-4.02(m,4H,CH2NCH2 in thiomorpholine),3.78-3.48(br,2H,CH 2 CHC=O inpyrrolidine),3.16-1.96(m,2H,CH 2 CHC=O in pyrrolidine),3.04-2.81(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C16H24N3OS calculated 306.1627, found [ M-2HCl + H]+306.1635.
Example 10
The compound 104- { [ (2S,4S) -4- (3-nitrophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (3-nitrophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 10b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.101g,0.32mmol) and 3-nitrochlorobenzene (0.053g,0.34mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.060g,0.63mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed for 10 hours under an argon atmosphere, cooled to room temperature, and insoluble matter in the reaction system was filtered off and concentrated under reduced pressure. The crude product was isolated by column chromatography using a mixture of petroleum ether and ethyl acetate (V: V = 1: 1) as eluent to give intermediate 10b as a yellow oil in a yield of 65.9% as 92 mg.
Second step preparation of 4- { [ (2S,4S) -4- (3-nitrophenyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine dihydrochloride (Compound 10)
Using 10b (92mg,0.21mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 10 was obtained in the form of a yellow powder (62 mg) with a yield of 72.2%. m.p.237-239 ℃,
1H NMR(DMSO-d6,300MHz)δ:7.44-7.37(m,3H,aromatic),7.02(d,J=8.4Hz,1H,aromatic),4.66(m,1H,CHC=O),4.26-4.22(m,1H,CHNH in pyrrolidine),3.73-3.49(4H,CH2NCH2 in thiomorpholine),3.15-2.82(m,2H,CH 2 NH in pyrrolidine),2.72-1.65(m,2H,CH 2 CHC=O in pyrrolidine),2.60-2.56(m,4H,CH2SCH2 inthiomorpholine).HR-MS(ESI-TOF+):C15H21N4O3s calculated 337.1329, found [ M-2HCl + H]+337.1337.
Example 11
The compound 114- { [ (2S,4S) -4- (pyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (pyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 10b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.101g,0.32mmol) and 2-chloropyridine (0.038g,0.34mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.060g,0.63mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed for 10 hours under an argon atmosphere, cooled to room temperature, and insoluble matter in the reaction system was filtered off and concentrated under reduced pressure. The crude product was isolated by column chromatography using a mixture of petroleum ether and ethyl acetate (V: V = 1: 1) as eluent to give intermediate 11b as a yellow oil in a yield of 61.4% as 77 mg.
Second step preparation of 4- { [ (2S,4S) -4- (pyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 11)
Using 11b (77mg,0.196mmol) as a starting material, the same procedures as in the second step of example 1 were carried out to give compound 11 as a pale yellow solid, 67mgThe yield thereof was found to be 85.2%. m.p.183-185 deg.c,
1H NMR(DMSO-d6,300MHz)δ:8.00(d,J=8.7Hz,1H in pyridine),7.91(d,J=6.0Hz,1H in pyridine),7.11(d,J=9.3Hz,1H in pyridine),7.00(t,J=6.6Hz,1H inpyridine),4.74-4.68(m,1H,CHC=O),3.90(m,1H,CHNH in pyrrolidine),3.83-3.81(m,4H,CH2NCH2 in thomorpholine),3.56-3.05(m,2H,CH 2 NH in pyrrolidine),2.69-2.61(m,4H,CH2SCH2 in thiomorpholine),2.4-1.96(m,2H,CH 2 CHC=O inpyrrolidine).HR-MS(ESI-TOF+):C14H21N4OS calculated 293.1431, found [ M-3HCl + H]+293.1436.
Example 12
The compound 124- { [ (2S,4S) -4- (5-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (5-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 12b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.102g,0.33mmol) and 2-chloro-5-cyanopyridine (0.046g,0.34mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.060g,0.63mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed under an argon atmosphere for 10 hours, cooled to room temperature, and insoluble matter was filtered off from the reaction system and concentrated under reduced pressure. The crude product was separated by column chromatography using a mixture of petroleum ether and ethyl acetate (V: V = 1: 1) as eluent to give the intermediate 12b as a yellow oil 69mg, 50.1% yield.
Second step preparation of 4- { [ (2S,4S) -4- (5-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 12)
Using 12b (69mg,0.16mmol) as a starting material, by the similar procedure as in the second step in example 1, Compound 12 was obtained as a pale yellow solid, 51mg, in 74.8% yield. m.p.102-104 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.46(s,1H in pyridine),7.77(d,J=8.7Hz,1Hin pyridine),6.61(d,J=9.0Hz,1H in pyridine),4.68(m,1H,CHC=O),3.78-3.72(m,4H,CH2NCH2 in thomorpholine),3.50(m,1H,CHNH in pyrrolidine),3.84-2.17(m,2H,CH 2 NH in pyrrolidine),2.73-1.80(m,2H,CH2CHC=O in pyrrolidine),2.61-2.50(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C15H20N5OS calculated 318.1383, found [ M-3HCl + H]+318.1387.
Example 13
The compound 134- { [ (2S,4S) -4- (3-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (3-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 13b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.102g,0.33mmol) and 2-chloro-5-cyanopyridine (0.046g,0.34mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.060g,0.66mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed under an argon atmosphere for 10 hours, cooled to room temperature, and insoluble matter was filtered off from the reaction system and concentrated under reduced pressure. The crude product was isolated by column chromatography using a mixture of petroleum ether and ethyl acetate (V: V = 1: 1) as eluent to give intermediate 13b as a yellow oil in 47.2% yield (65 mg).
Second step preparation of 4- { [ (2S,4S) -4- (3-cyanopyridin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 13)
Using 13b (65mg,0.156mmol) as a starting material, by the similar procedure as in the second step in example 1, Compound 13 was obtained as a pale yellow solid (43 mg, yield 64.7%). m.p.156-158 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.32(d,J=4.8Hz,1H in pyridine),7.98(d,J=7.5Hz,1H in pyridine),7.21(d,J=7.2Hz,1H in pyridine),4.85-4.80(m,1H,CHC=O),4.65(m,1H,CHNH in pyrrolidine),3.83-3.70(m,4H,CH2NCH2 inthomorpholine),3.46-3.30(m,2H,CH 2 NH in pyrrolidine),2.84-1.86(m,2H,CH 2 CHC=O in pyrrolidine),2.72-2.60(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C15H20N5OS calculated 318.1383, found [ M-3HCl + H]+318.1385.
Example 14
The compound 144- { [ (2S,4S) -4- (quinolin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (quinolin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 14b
4- { [ (2S,4S) -4-amino-N-t-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.102g,0.32mmol) and 2-chloroquinoline (0.054g,0.33mmol) were dissolved in 15mL of anhydrous toluene, and sodium t-butoxide (0.060g,0.63mmol), Davep (3mg) and palladium acetate (10mg) were added, and the mixture was refluxed for 10 hours under an argon atmosphere, cooled to room temperature, and insoluble matter in the reaction system was filtered off and concentrated under reduced pressure. The crude product was isolated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) as eluent to give intermediate 14b as yellow crystals 101mg in 71.4% yield.
Second step preparation of 4- { [ (2S,4S) -4- (quinolin-2-yl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 14)
Using 14b (101mg,0.23mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 14 was obtained in 96mg as an off-white solid with a yield of92.5%。m.p.120-122℃,
1H NMR(DMSO-d6,300MHz)δ:8.37(d,J=8.7Hz,1H in quinoline),8.28(br,1H in quinoline),7.94(d,J=7.8Hz,1H in quinoline),7.81(t,J=7.5Hz,1H inquinoline),7.53(t,J=7.5Hz,1H in quinoline),7.17(d,J=8.7Hz,1H in quinoline),5.03(br,1H,CHC=O),4.73(m,1H,CHNH in pyrrolidine),3.82-3.70(m,4H,CH2NCH2 in thomorpholine),3.51-3.45(m,2H,CH 2 NH in pyrrolidine),3.15-2.71(m,2H,CH 2 CHC=O in pyrrolidine),2.65-2.51(m,4H,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C18H23N4OS calculated 343.1587, found [ M-3HCl + H]+343.1588.
Example 15
Compound 154- { [ (2S,4S) -4- (4-Methylbenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine hydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (4-methylbenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 15b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.156g,0.50mmol) was dissolved in 15mL of anhydrous dichloromethane, triethylamine (0.15g,1.5mmol) was added, the reaction system was cooled to 0 ℃ or lower, p-toluenesulfonyl chloride (0.114g,0.60mmol) was slowly added dropwise, the reaction was continued at low temperature for 2 hours until completion, the reaction solution was warmed to room temperature, the organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was separated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 15b as a white crystal 176mg, yield 75.1%.
Second step preparation of 4- { [ (2S,4S) -4- (4-Methylbenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine hydrochloride (Compound 15)
Using 15b (150mg,0.32mmol) as a starting material, by a procedure similar to the second step in example 1, compound 15 was obtained in the form of an off-white solid (118 mg) with a yield of 90.8%. m.p.209-211 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.11(d,J=6.0Hz,1H,NHSO2),7.73(d,J=7.8Hz,2H,aromatic),7.44(d,J=7.8Hz,2H,aromatic),4.50(t,J=8.7Hz,3H,CHC=O),3.81-3.68(m,5H,CH2NCH2 in thiomorpholine,CHNH in pyrrolidine),3.63(s,3H,CH3),3.04-3.21(m,2H,CH 2 NH in pyrrolidine);2.50(br,4H,CH2SCH2 inthiomorpholine),2.46-1.56(m,2H,CH 2 CHC=O in pyrrolidine).HR-MS(ESI-TOF+):C16H24N3O3S2calculated value 370.1254, found [ M-HCl + H]+370.1251.
Example 16
The compound 164- { [ (2S,4S) -4- (4-Nitrobenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine hydrochloride
First step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- (4-nitrobenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine 16b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.156g,0.50mmol) was dissolved in 15mL of anhydrous dichloromethane, triethylamine (0.15g,1.50mmol) was added, the reaction system was cooled to below 0 ℃, p-nitrobenzenesulfonyl chloride (0.128g,0.58mmol) was slowly added dropwise, the reaction was continued at low temperature for 4 hours until completion, the reaction solution was warmed to room temperature, the organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was separated by column chromatography using petroleum ether/ethyl acetate (V: V = 1: 1) mixture as eluent to give intermediate 16b as a white crystal 170mg with a yield of 68.0%.
Second step preparation of 4- { [ (2S,4S) -4- (4-Nitrobenzenesulfonyl-amino) -pyrrol-2-yl ] -formyl } thiomorpholine hydrochloride (Compound 16)
Using 16b (150mg,0.30mmol) as a starting material, by a procedure similar to the second step in example 1, compound 16 was obtained in the form of an off-white solid (107 mg) with a yield of 81.8%. m.p.209-211 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.61(br,1H,NH),8.45(d,J=8.7Hz,2H,aromatic),8.09(d,J=9.0Hz,2H,aromatic),4.50(t,J=9.3Hz,1H,CHC=O),3.86(br,1H,CHNH in pyrrolidine),3.74&3.61(s,2H)(s,2H,CH2NCH2 in thiomorpholine),3.26-3.01(m,2H,CH 2 NH in pyrrolidine),2.591.63(m,6HCH 2 CHC=O in pyrrolidine,CH2SCH2 in thiomorpholine).HR-MS(ESI-TOF+):C15H21N4O5S2calculated value 401.0948, found [ M-HCl + H]+401.0953.
Example 17
The compound 174- { [ (2S,4S) -4- [ (5-cyanopyridin-2-yl) -piperidin-4-yl-amino ] -pyrrol-2-yl ] -formyl } thiomorpholine tetrah-ydrochloride
First step preparation of 5-cyanopyridin-2-yl-piperidin-4-one 7a
4-Piperidinone hydrochloride (0.272g,2.0mmol) and 5-cyano-2-chloropyridine (0.276g,2.0mmol) were dissolved in 20mL of anhydrous DMF, potassium carbonate (0.56g,4.1mmol) was added, the reaction was heated at 80 ℃ for 10 hours, 30mL of ice water was added to the reaction system and stirred for 30min, extraction was performed with ethyl acetate, the organic layers were combined, washed with water and saturated brine, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Separating the crude product with column, eluting with petroleum ether/ethyl acetate (V: V = 1: 1) mixture to obtain intermediate 7a as pale yellow solid 280mg with 69.7% yield
Second step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- [ (5-cyanopyridin-2-yl) -piperidin-4-yl-amino) ] -pyrrol-2-yl ] -formyl } thiomorpholine 17b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.103g,0.33mmol) and 7a (0.066g,0.33mmol) were dissolved in 10mL of dichloromethane, and after complete dissolution, a small amount of AcOH was added to the reaction pH =3-5, stirred at room temperature for 3 hours, the reaction was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.211g,1.0mmol) was added, warmed to room temperature, and stirred for 8 hours until the reaction was complete. To the reaction solution was added 20mL of water, followed by extraction with dichloromethane, and the organic layers were combined, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is separated by column chromatography, and a dichloromethane-methanol (V: V = 50: 1) mixed solution is used as an eluent. Intermediate 17b was obtained as a pale yellow solid 112mg, yield 67.7%.
Third step preparation of 4- { [ (2S,4S) -4- [ (5-cyanopyridin-2-yl) -piperidin-4-yl-amino ] -pyrrol-2-yl ] -formyl } thiomorpholine tetrahydrate hydrochloride (Compound 17)
Using 17b (112mg,0.22mmol) as a starting material, by a procedure similar to the second step in example 1, Compound 17 was obtained in the form of an off-white solid (105 mg) with a yield of 87.4%. m.p. > 250 ℃,
1H NMR(DMSO-d6,300MHz)δ:8.52(s,1H in pyridine),7.91(s,1H,inpyridine),7.04(m,1H,in pyridine),4.67(s,1H CHC=O),4.57(br,2H,CHNHCH),3.82-3.56(m,8H,CH2NCH2 in piperidine,CH2NCH2 in thiomorpholine),3.00-2.66(m,8H CH 2 CHCH 2 in piperidine,CH2SCH2 in thiomorpholine),1.97-1.60(m,4H,CH 2 NH,CH 2 CH in pyrrolidine).HR-MS(ESI-TOF+):C20H30N6OS calculated 401.2118, found [ M-4HCl + H]+401.2056.
Example 18
The compound 184- { [ (2S,4S) -4- [ (4-cyanobenzyl) -piperidin-4-yl-amino ] -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride
First step preparation of 5-cyanobenzylpiperidin-4-one 8a
4-Piperidinone hydrochloride (0.272g,2.0mmol) and 5-cyanobenzyl chloride (0.301g,2.0mmol) were dissolved in 20mL of anhydrous DMF, potassium carbonate (0.56g,4.1mmol) was added, the reaction system was heated at 80 ℃ for 10 hours, 30mL of ice water was added to the reaction system and stirred for 30min, extraction was performed with ethyl acetate, the organic layers were combined, washed with water and saturated brine, respectively, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Separating the crude product by silica gel column chromatography, eluting with petroleum ether/ethyl acetate (V: V = 1: 1) mixture to obtain intermediate 5-cyanobenzylpiperidine-4-one 8a as pale yellow solid 362mg with 84.6% yield
Second step preparation of 4- { [ (2S,4S) -N-tert-Butoxycarbonyl-4- [ (4-cyanobenzyl) -piperidin-4-yl-amino ] -pyrrol-2-yl ] -formyl } thiomorpholine 18b
4- { [ (2S,4S) -4-amino-N-tert-butoxycarbonyl-pyrrol-2-yl ] -formyl } thiomorpholine 6a (0.103g,0.33mmol) and 8a (0.068g,0.32mmol) were dissolved in 10mL of dichloromethane, and after complete dissolution, a small amount of AcOH was added to the reaction pH =3-5, stirred at room temperature for 3 hours, the reaction was cooled to below 0 deg.C, sodium triacetoxyborohydride (0.211g,1.0mmol) was added, warmed to room temperature, and stirred for 10 hours to complete the reaction. To the reaction solution was added 20mL of water, followed by extraction with dichloromethane, and the organic layers were combined, washed with a saturated sodium bicarbonate solution and a saturated brine, respectively, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is separated by column chromatography, and a dichloromethane-methanol (V: V = 50: 1) mixed solution is used as an eluent. Intermediate 18b was obtained as a pale yellow solid, 106mg, yield 62.5%.
Third step preparation of 4- { [ (2S,4S) -4- [ (4-cyanobenzyl) -piperidin-4-yl-amino ] -pyrrol-2-yl ] -formyl } thiomorpholine trihydrochloride (Compound 18)
Using 18b (106mg,0.21mmol) as a starting material, by a procedure similar to the second step in example 1, compound 18 was obtained in the form of an off-white solid (88 mg, yield 80.3%). m.p. > 250 ℃,
1H NMR(DMSO-d6,300MHz)δ:7.97(d,J=8.4Hz,2H,aromatic),7.83(d,J=8.4Hz,2H,aromatic),4.67(br,1H CHC=O),4.36(br,1H,NHCH in pyrrolidine),4.07-3.99(m,4H,CH2NCH2 in piperidine),3.78(br,1H,NHCH in piperidine),3.44-3.71(m,8H,Ar-CH2,CH 2 NH in pyrrolidine,CH2NCH2 in thiomorpholine),2.86-2.24(m,8H,CH 2 CHCH 2 in piperidine,CH2NCH2 in thiomorpholine),2.07(br,2H,CH 2 CH in pyrrolidine).HR-MS(ESI-TOF+):C22H32N5OS calculated 414.2322, found [ M-3HCl + H]+414.2246.
Test examples section
Test example 1 in vitro screening method for DPP-IV inhibitor
Reagent:
1. reaction substrate: Gly-Pro-p-nitroanilide hydrochloride (Sigma, G0513) using ddH2Dissolving O to obtain 0.026M stock solution, and storing at-20 deg.C in dark.
DPP-IV enzyme: recombinant human DPP-IV protein (Sigma, D4943) is preserved at-20 ℃.
3. A sample to be tested: DMSO is dissolved in 10-2M, storing at 4 ℃.
4. Positive control drug: sitagliptin is dissolved in DMSO to 10-2M, storing at 4 ℃.
5.2×Hepes buffer:1.6g NaCl,0.074g KCl,0.027g Na2HPO4·2H2O, 0.2g Glucose, 1g Hepes in 90ml ddH2Adjusting pH to 7.05 with NaOH, diluting to 100ml, filtering at 0.22 μm, and storing at 4 deg.C.
Tis-HCl buffer: 6.06g Tris in 1L distilled water, adjusted to pH 8.0 with HCl.
Detection method
ddH for sample and positive drug Sitagliptin2Diluting O to 10%-4M, DPP-IV was formulated with Tis/HCl buffer (pH = 8.0) at a concentration of 2 mU/ml. The substrate Gly-Pro-p-nitroanilide working solution was diluted with Hepes buffer (pH = 7.05) at a concentration of 0.26 mM. The experiment is provided with a negative control group, a positive control group and a sample group. The total volume of the reaction was 100. mu.l, in which ddH was added to the negative control group2O10 mul, DPP-IV enzyme working solution 50 mul and substrate working solution 40 mul; adding Sitagliptin solution 10 μ l, DPP-IV enzyme working solution 50 μ l and substrate working solution 40 μ l into the positive control group; the sample set was loaded with 10. mu.l of sample solution, 50. mu.l of DPP-IV working solution and 40. mu.l of substrate working solution. The inhibition of DPP-IV by samples was evaluated by monitoring the change in absorbance of the reaction at 405nm at 37 ℃ for 60minThe application is as follows.
The inhibition rate of the sample on DPP-IV is calculated as follows:
inhibition (%) = (Δ OD)60-0Negative control group-. DELTA.OD60-0Sample set)/Δ OD60-0Negative control group X100%
The positive control Sitagliptin is generally considered to be at 10-5The inhibition rate of M is 90-100%, the reaction of the experiment is reliable, and the inhibition rate of the sample is more than 40%, so that the reaction is effective.
Positive Compound IC
50
The calculation of (2):
1. for the primary screening (concentration of test compound 10)-5M) active compounds (i.e. inhibitory activity greater than 50%), with different concentration gradients set i.e. 10-8,10-7,10-6And 10-5M DPP-IV inhibition experiments are carried out.
2. Drawing a concentration-reaction curve by using the reaction concentration and the inhibition rate of the compound, statistically processing the curve to obtain a fitting formula, wherein Y is the inhibition rate, X is the concentration of the compound, and when Y is 50 percent, namely the activity of 50 percent of the inhibition rate is reached, the corresponding concentration of the compound is the half effective Inhibition Concentration (IC) of the compound50) The test results are shown in Table 1.
TABLE 1 results of enzyme level Activity assay of Compounds of examples of the invention
And (4) conclusion:
of the compounds tested, 12 examples had greater than 50% in vitro DPP-IV inhibitory activity, of which 9 examples had IC50Reaching the level of μ M. Example 14 has the highest in vitro DPP-IV inhibitory activity.
Test example 2 DPP-IV inhibitor selectivity evaluation method (DPP 8/9 inhibitory Activity in vitro evaluation method)
1. Reaction substrate: the method is the same as the DPP-IV inhibitor in vitro screening method.
DPP8/9 enzyme: the recombinant human DPP8/9 protein is purified and freeze-dried and then stored at-20 ℃.
3. Sample preparation: the method is the same as the DPP-IV inhibitor in vitro screening method.
4. Positive control drug: the compound (S) -4- (2-amino- (R) -3-methylpentanoyl) isoindoline hydrochloride was dissolved in DMSO to give a solution of 10-2M, storing at 4 ℃.
5.2 × Hepes buffer: the method is the same as the DPP-IV inhibitor in vitro screening method.
Tis/HCl buffer: the method is the same as the DPP-IV inhibitor in vitro screening method.
Evaluation method
Samples and Positive drugs ddH2Diluting O to 10%-4M, DPP8 enzyme was formulated with Tis/HCl buffer (pH = 8.0) at a concentration of 60ng/ml and DPP9 enzyme was formulated at a concentration of 40 ng/ml. The substrate Gly-Pro-p-nitroanilide working solution was diluted with Hepes buffer (pH = 7.05) at a concentration of 0.52 mM. The experiment is provided with a negative control group, a positive control group and a sample group. The total volume of the reaction was 100. mu.l, in which ddH was added to the negative control group2O10 mul, DPP8/9 enzyme working solution 50 mul and substrate working solution 40 mul; adding 10 mul of positive control solution, 50 mul of DPP8/9 enzyme working solution and 40 mul of substrate working solution into a positive control group; the sample set was loaded with 10. mu.l of sample solution, 50. mu.l of DPP8/9 enzyme working solution and 40. mu.l of substrate working solution. The selectivity of the DPP-IV inhibitor, i.e. DPP8/9 inhibition, was evaluated by monitoring the change in absorbance of the reaction at 405nm at 37 ℃ for 60 min. The selectivity of the DPP-IV inhibitor (DPP 8/9 inhibitory activity) is calculated as follows:
inhibition (%) = (Δ OD)60-0Negative control group-. DELTA.OD60-0Sample set)/Δ OD60-0Negative control group X100%
The test results are shown in Table 2
The inhibition rate of the positive drug at the same concentration is 96.7%.
And (4) conclusion:
11 tested compounds with DPP-IV inhibitory activity have no obvious inhibitory activity on DPP8/9, which shows that the 11 compounds have high DPP-IV selectivity.
Claims (9)
1. A compound represented by the general formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts thereof,
wherein,
r is selected from hydrogen and C1-6Alkyl radical, C3-8Cycloalkyl, aryl-C1-3Alkyl, aryl-C3-8Cycloalkyl, heteroaryl-C1-3Alkyl radicalheteroaryl-C3-8Cycloalkyl, heterocycloalkyl containing from 3 to 8 (e.g. 3 to 7, 3 to 6, 3 to 5, or 3 to 4) carbon atoms and from 1 to 3 (e.g. 1 to 2, 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, sulfur, aryl-C3-8Heterocycloalkyl, heteroaryl-C3-8Heterocycloalkyl, benzyl-C3-8Heterocycloalkyl radical, C1-6Alkyl formyl radical, C3-8Cycloalkyl-formyl, aryl-formyl, benzyl-formyl, heteroaryl-formyl, C1-6Alkylsulfonyl radical, C3-8Cycloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, benzylsulfonyl;
wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
2. A compound according to claim 1, said compound being represented by the general formula (IA), and stereoisomers and pharmaceutically acceptable salts thereof
Wherein,
r is selected from hydrogen and C1-6Alkyl radical, C3-8Cycloalkyl, aryl-C1-3Alkyl, aryl-C3-8Cycloalkyl, heteroaryl-C1-3Alkyl, heteroaryl-C3-8Cycloalkyl, heterocycloalkyl containing from 3 to 8 (e.g. 3 to 7, 3 to 6, 3 to 5, or 3 to 4) carbon atoms and from 1 to 3 (e.g. 1 to 2, 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, sulfur, aryl-C3-8Heterocycloalkyl, heteroaryl-C3-8Heterocycloalkyl, benzyl-C3-8Heterocycloalkyl radical, C1-6Alkyl formyl radical, C3-8Cycloalkylcarboxoyl radicalArylformyl, benzylformyl, heteroarylformyl, C1-6Alkylsulfonyl radical, C3-8Cycloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, benzylsulfonyl;
wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
3. A compound according to any one of claims 1 to 2 and stereoisomers thereof, pharmaceutically acceptable salts thereof, wherein
R is selected from C1-6Alkyl, aryl, heteroaryl, C3-8Nitrogen-containing heterocycloalkyl, aryl-C1-3Alkyl, heteroaryl-C1-3Alkyl, arylsulfonyl, heteroaryl-C3-8Nitrogen-containing heterocycloalkyl, benzyl-C3-8A nitrogen-containing heterocycloalkyl group;
wherein said alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and benzyl are optionally substituted with 1 to 4 (e.g., 1 to 3, 1 to 2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
4. A compound according to any one of claims 1 to 3 and stereoisomers thereof, pharmaceutically acceptable salts thereof, wherein
R is C1-6Alkyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted phenyl-C1-3Alkyl, substituted or unsubstituted pyridyl-C1-3An alkyl group, a carboxyl group,substituted or unsubstituted pyridyl-piperidinyl, substituted or unsubstituted benzyl-piperidinyl, substituted or unsubstituted phenylsulfonyl.
Wherein said alkyl, piperidinyl, phenyl, pyridinyl, quinolinyl, and benzyl are optionally substituted with 1-4 (e.g., 1-3, 1-2, 1, 2, or 3) groups selected from: H. hydroxy, halogen, cyano, amino, nitro, trifluoromethyl, C1-6Alkyl radical, C1-6Alkyloxy, and NR1R2And R is1And R2Independently selected from H, C1-6An alkyl group.
6. a process for the preparation of a compound according to any one of claims 1 to 5, comprising the steps of:
subjecting the compound of formula 6a to a substitution reaction with a halide RX (X is halogen) in a base (e.g. potassium carbonate) and a suitable solvent (e.g. N, N-dimethylformamide) at a temperature of 60 ℃ to 90 ℃ (e.g. 60 ℃ to 70 ℃, 70 ℃ to 80 ℃ or 80 ℃ to 90 ℃) for about 4 to 12 hours to give a compound of formula b; or,
reacting a compound of formula 6a with an aldehyde or ketone containing an R group under acidic conditions (e.g., acetic acid) at a temperature of-10 ℃ to 40 ℃ (e.g., -10 ℃ to 35 ℃, -5 ℃ to 30 ℃, -5 ℃ to 25 ℃, or 0 ℃ to 25 ℃) for about 2-6 hours to provide a compound of formula b; or,
reacting the compound of formula 6a with a sulfonyl chloride containing an R group in a base (e.g., triethylamine) and a suitable solvent (e.g., dichloromethane) at a temperature of-20 ℃ to 0 ℃ (e.g., -20 ℃ to 0 ℃, -15 ℃ to 0 ℃, or-5 ℃ to 0 ℃) for about 2-6 hours to provide a compound of formula b; or,
reacting the compound of formula 6a with an R group-containing halogenated aromatic compound using a suitable ligand (e.g., Davep) and a catalyst (e.g., palladium acetate) in a base (e.g., sodium t-butoxide) and a suitable solvent (e.g., toluene) at a temperature of 90 ℃ to 150 ℃ (e.g., 100 ℃ to 150 ℃, 110 ℃ to 150 ℃ or 130 ℃ to 150 ℃) for about 8-16 hours to provide the compound of formula b;
the Boc protecting group is removed from the compound of formula b in ethyl acetate hydrochloride solution at a temperature of 10 ℃ to 40 ℃ (e.g., 10 ℃ to 35 ℃, 15 ℃ to 30 ℃,20 ℃ to 30 ℃ or 20 ℃ to 25 ℃) to provide the compound of the invention of formula IA. If racemic 6a is used as the raw material, the compound of the invention shown in the formula I is obtained according to the steps and the method.
Wherein R is as defined in any one of claims 1 to 5.
7. A pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of a compound of any one of claims 1 to 5, and stereoisomers thereof, pharmaceutically acceptable salts thereof, and optionally one or more pharmaceutically acceptable carriers or excipients.
8. Use of a compound according to any one of claims 1 to 5, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 7, for the manufacture of a medicament for use in a method for the treatment and/or prevention of diseases or conditions associated with DPP-IV hyperactivity or DPP-IV overexpression.
9. Use according to claim 8, wherein the disease or condition associated with DPP-IV hyperactivity or DPP-IV overexpression is a disease or condition selected from the group consisting of: diabetes, hyperglycemia, non-insulin dependent diabetes, type 2 diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101596323A CN103420981A (en) | 2012-05-21 | 2012-05-21 | Substituted-pyrrolidinyl-contained thiomorpholine compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101596323A CN103420981A (en) | 2012-05-21 | 2012-05-21 | Substituted-pyrrolidinyl-contained thiomorpholine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103420981A true CN103420981A (en) | 2013-12-04 |
Family
ID=49646405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012101596323A Pending CN103420981A (en) | 2012-05-21 | 2012-05-21 | Substituted-pyrrolidinyl-contained thiomorpholine compounds |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103420981A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211685A (en) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | Thiomorpholine compounds containing substituted pyrrole alkyl groups |
CN105085358A (en) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | 4-substituted pyrrolidine formyl thiomorpholine DPP-IV (Dipeptidyl Peptidase IV) inhibitor |
CN105085359A (en) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | Nitrogen-containing heterocyclic substituted pyrrolidine formyl thiomorpholin DPP-IV inhibitor |
CN114436930A (en) * | 2022-02-15 | 2022-05-06 | 重庆市碚圣医药科技股份有限公司 | Synthesis method of Boc-L-hydroxyproline |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1441779A (en) * | 2000-08-10 | 2003-09-10 | 三菱制药株式会社 | Proline derivatives and use thereof as drugs |
JP2007131570A (en) * | 2005-11-09 | 2007-05-31 | Mitsubishi Pharma Corp | Novel aminopyrrolidine derivative |
CN101535297A (en) * | 2006-07-14 | 2009-09-16 | 株式会社Lg生命科学 | Melanocortin receptor agonists |
CN102282141A (en) * | 2008-11-12 | 2011-12-14 | 株式会社Lg生命科学 | Melanocortin receptor agonists |
CN102453001A (en) * | 2010-10-22 | 2012-05-16 | 中国医学科学院药物研究所 | Sulfomorpholine compounds, preparation method thereof and purpose thereof |
-
2012
- 2012-05-21 CN CN2012101596323A patent/CN103420981A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1441779A (en) * | 2000-08-10 | 2003-09-10 | 三菱制药株式会社 | Proline derivatives and use thereof as drugs |
JP2007131570A (en) * | 2005-11-09 | 2007-05-31 | Mitsubishi Pharma Corp | Novel aminopyrrolidine derivative |
CN101535297A (en) * | 2006-07-14 | 2009-09-16 | 株式会社Lg生命科学 | Melanocortin receptor agonists |
CN102282141A (en) * | 2008-11-12 | 2011-12-14 | 株式会社Lg生命科学 | Melanocortin receptor agonists |
CN102453001A (en) * | 2010-10-22 | 2012-05-16 | 中国医学科学院药物研究所 | Sulfomorpholine compounds, preparation method thereof and purpose thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211685A (en) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | Thiomorpholine compounds containing substituted pyrrole alkyl groups |
CN105085358A (en) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | 4-substituted pyrrolidine formyl thiomorpholine DPP-IV (Dipeptidyl Peptidase IV) inhibitor |
CN105085359A (en) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | Nitrogen-containing heterocyclic substituted pyrrolidine formyl thiomorpholin DPP-IV inhibitor |
CN114436930A (en) * | 2022-02-15 | 2022-05-06 | 重庆市碚圣医药科技股份有限公司 | Synthesis method of Boc-L-hydroxyproline |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10300058B2 (en) | Tyrosine kinase inhibitor and uses thereof | |
TWI809334B (en) | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2 -amine salt | |
CA3018346A1 (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
WO2004064730A2 (en) | Compounds, compositions and methods | |
EA015835B1 (en) | 4-oxa(thia)methylpiperidine derivatives, use thereof as antidiabetic compounds | |
US10654834B2 (en) | Non-systemic TGR5 agonists | |
US20200002318A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
JP2013253019A (en) | New piperidine derivative and pharmaceutical containing the same | |
US20230278958A1 (en) | Tricyclic heterocycles | |
TW202346289A (en) | Compounds as glp-1r agonists | |
CN103420981A (en) | Substituted-pyrrolidinyl-contained thiomorpholine compounds | |
US11655235B2 (en) | Pyrrolidine and piperidine compounds | |
US20210163478A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
JP2011136942A (en) | Novel substituted pyrimidine derivative and medicine comprising the same | |
CA2841897A1 (en) | Novel compound having parp inhibitory activity | |
CN116283918A (en) | Bifunctional compound for degrading receptor tyrosine kinase and application thereof | |
CN104211702B (en) | Substituted xanthine class compound and its preparation method and application | |
CN104211685A (en) | Thiomorpholine compounds containing substituted pyrrole alkyl groups | |
CN105085359A (en) | Nitrogen-containing heterocyclic substituted pyrrolidine formyl thiomorpholin DPP-IV inhibitor | |
RU2815480C1 (en) | ISOQUINOLINONE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-ribose)POLYMERASE-1, CONTAINING THEM AS ACTIVE INGREDIENT | |
RU2803455C1 (en) | Pyrrolidine and piperidine compounds | |
KR102293986B1 (en) | Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating poly(ADP-ribose)polymerase-1 related diseases containg the same as an active ingredient | |
US20240287032A1 (en) | Novel heterocyclic compound and use thereof | |
KR101664969B1 (en) | 4-(2-Benzyloxyphenyl)-1-(pyrrolidin-3-yl)-1,2,3-triazole derivatives | |
CN105085358A (en) | 4-substituted pyrrolidine formyl thiomorpholine DPP-IV (Dipeptidyl Peptidase IV) inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131204 |
|
WD01 | Invention patent application deemed withdrawn after publication |